<unk>  is a GLP-1 receptor agonist that is FDA approved for the treatment of type 2 diabetes mellitus.   Common adverse reactions include injection site mass, injection site pruritus, injection site reaction, hypoglycemia, constipation, diarrhea, indigestion, nausea, vomiting, antibody development, asthenia, dizziness, nervousness, headache.
Exenatide
Liraglutide
Linagliptin
Pioglitazone
Buformin
Insulin degludec
Rosiglitazone
Canagliflozin